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1) Department of Medical Microbiology and Infection, Queen Alexandra Hospital and 2) University of Portsmouth, Portsmouth, UKAbstractFaecal microbiota transplantation (FMT) has been shown to be highly effective in treating recurrent Clostridium difﬁcile infection, but to date
there have been no data from the United Kingdom. An electronic survey was developed at Portsmouth Hospitals’ National Health Service
(NHS) Trust and sent out to UK hospital specialists utilizing the contact databases of the British Infection Association and the Royal College of
Gastroenterologists. A total of 162 responses were received, representing nearly one in every seven of the United Kingdom’s infection
specialists and a response from one in every two UK NHS acute trusts or boards. Ninety-six per cent believe that the evidence base
supports the use of FMT, and 94% reported consulting on at least one patient a year in whom they would recommend FMT. However,
only 22% reported FMT use in their institution in the last 10 years, and 6% reported performing more than ten FMTs in the last 10
years. Concerns with patient acceptance, donor selection, availability of screened faecal solution, feasibility of procedure and availability of
local expertise were reported as inhibiting the use of FMT. More than 90% of respondents would like access to regional guidelines,
prescreened faecal solution and expert advice to facilitate implementation, and more than two thirds of respondents would support a
regional FMT referral centre. A large gap exists in the United Kingdom between physicians desire to use FMT and the ability and facilities
to provide it as a therapy at the bedside.
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E-mail: robert.porter@porthosp.nhs.ukIntroductionClostridium difﬁcile infection (CDI) is a major cause of mortality
and morbidity. C. difﬁcile was recorded as the underlying cause
of death for 10 258 patients in England and Wales between
2007 and 2011, and a contributing factor in a further 12 687
deaths. Between 2009 and 2011, 91% of CDI deaths in England
and Wales occurred in National Health Service (NHS)Microbiol Infect 2015; 21: 578–582
own Copyright © 2015 Clinical Microbiology and Infection published by Elsevier Ltd on behal
p://dx.doi.org/10.1016/j.cmi.2015.01.020hospitals. Most deaths occur in older people, with those aged
85 and over having the highest mortality rate (1099 per million
population in 2009–2011) (http://www.ons.gov.uk/ons/
dcp171778_276892.pdf). Mortality estimates have varied
widely, and rates have generally reported to have increased
with the widespread circulation of the 027/NAP1/BI strain, with
30 day all-cause mortality of 23% to 29% in an endemic setting
[1–3]. Mortality rates in hospitalized CDI patients from Holland
in a nonendemic setting were recently published, with a 30-day
all-cause mortality rate of 13% and a 1-year mortality rate of
37% [4].
A review of the economic burden of CDI in 2012 reported
the cost of a single case of CDI to be between £4577 ($6943)
and £8843 ($13 414) at 2010 values (approximately £5000 to
£10 000 in 2014), with an average hospital length of stay off of European Society of Clinical Microbiology and Infectious Diseases. All rights reserved
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episodes of CDI may cost the local healthcare economy
signiﬁcantly more than this [6,7]. Faecal microbiota trans-
plantation (FMT) has been shown to be highly cost effective
compared to standard therapy, with an incremental cost-
effectiveness ratio of over £10 000 ($17 016) relative to oral
vancomycin [8].
Recurrence occurs in approximately 22% of patients after a
ﬁrst episode of CDI [9,10]. FMT has increasingly been reported
as an effective treatment for recurrent CDI, with a 2011 sys-
tematic review of 317 patients across 27 case series and re-
ports showing an overall cure rate of 92% [11]. In 2013, a
Dutch group reported the ﬁrst randomized controlled trial of
FMT for recurrent CDI, which showed an overall cure rate of
94% compared to 31% for standard therapy with high-dose
vancomycin [12].
Although FMT appears to be effective, uptake may be
hampered by patient and physician concerns over the proce-
dure. Attitudes in the United Kingdom are unknown, but
concerns over the ‘yuck’ factor [13], as well as the disconnect
between physician beliefs and patient willingness to accept FMT
[14], have been explored in the United States. A survey of
gastroenterologists and infectious diseases physicians in the
Houston, Texas, area in the United States published in 2013
showed a desire for a local referral centre for FMT [15].
We developed a survey to explore the uptake of FMT within
the United Kingdom and to identify any barriers that might
prevent the use of FMT. We also asked about the desire for
support through availability of prescreened donor faecal solu-
tion, expert advice and regional referral centres.
The NHS provides free healthcare to all UK citizens and legal
immigrants, and supports a network of primary, secondary and
tertiary care providers. Portsmouth Hospitals’ NHS Trust is a
secondary and tertiary care provider for over 650 000 in-
dividuals on the south coast of England.MethodsSurvey development
The survey was developed at Portsmouth Hospitals’ NHS Trust
following a literature review of research and opinion articles
concerning FMT. It was designed to be completed in approxi-
mately 5 minutes and to explore the current uptake and need
for FMT and the attitudes of physicians to FMT. It asked about
current use of FMT and other common therapeutic measures
by UK physicians, asked physicians to determine how many
FMTs they might foresee using and asked about their beliefs
regarding FMT. After literature review, and from peer discus-
sion, 11 factors were identiﬁed that might inﬂuence FMTCrown Copyright © 2015 Clinical Microbiology and Infection published by Elsevier Ltd on behalfuptake, and questions regarding these factors were incorpo-
rated. The survey was administered using the web-based
KwikSurveys (http://www.kwiksurveys.com) site. The survey
data was downloaded to a CSV ﬁle and analysed using
descriptive statistics within Microsoft Excel.
Survey participants
The survey was targeted at consultants and senior trainees in
infection and gastroenterology. A short request for help
completing the survey with an attached hyperlink was for-
warded via e-mail with the help of the British Infection Asso-
ciation and the Royal College of Gastroenterologists. Mailings
occurred in December 2013 and June 2014, with survey re-
sponses accepted up until collation of results in July 2014.ResultsCharacteristics and caseload of respondents
A total of 161 complete or nearly complete (>75%) responses
were returned from 86 unique acute hospital trusts or NHS
boards. One incomplete response was excluded. A total of 142
responses were received from infection specialists, and a
further 19 responses were received from gastroenterologists
via the Royal College of Gastroenterologists. One hundred
sixty responses were from the United Kingdom, and 159 were
from physicians primarily working within the NHS. Table 1
shows the grade and specialty of respondent and the average
number of CDI consults performed per month.
Current treatment for CDI
Respondents were asked which therapies for CDI they had
personally recommended (Table 2), with 160 (99.4%) reporting
oral vancomycin, 112 (69.6%) ﬁdaxomicin, 43 (26.7%) colec-
tomy and 33 (20.5%) FMT.
When asked about current FMT use, 34/161 (21.1%) had
used it in the last year, and 36/161 (22.4%) had used it in the last
10 years. Of those who had used FMT in the last year, 28/161
(17.4%) had performed one to four FMTs, three (1.9%) had
performed ﬁve to nine FMTs and a further three (1.9%) more
than ten FMTs. Only nine respondents (5.6%) from four unique
trusts or boards (4.4%) reported performing more than ten
FMTs in the last 10 years.
Perceived need for FMT
In contrast to the low current usage of FMT, 130 (94.1%) of
respondents indicated that they saw at least one patient a year
who would be suitable for FMT in their institution, and 50
(37.0%) saw more than ﬁve per year. Only eight (5.8%) re-
ported seeing no suitable patients in a year; these eight were all
consultant infection specialists.of European Society of Clinical Microbiology and Infectious Diseases. All rights reserved,
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TABLE 3. Factors inﬂuencing use of faecal microbiota
TABLE 1. Specialty and grade of respondent
Specialty Grade n (%)
Average no. of CDI cases consulted per month
0 1–2 3–5 6–10 >10
Infection Consultant 104 (65) 1 (1) 41 (39) 43 (41) 15 (14) 4 (4)
Senior trainee 24 (15) 0 (0) 8 (33) 10 (42) 2 (8) 4 (17)
Gastroenterology Consultant 25 (16) 2 (8) 13 (52) 9 (36) 1 (4) 0 (0)
Senior trainee 4 (2) 0 (0) 4 (100) 0 (0) 0 (0) 0 (0)
Other 4 (2) 1 (25) 2 (50) 0 (0) 0 (0) 1 (25)
CDI, Clostridium difﬁcile infection.
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(93.6%) would recommend FMT in patients who had recur-
rent CDI and whose CDI had failed to respond to high-dose
pulse/tapered vancomycin, 72 (51.1%) in patients with CDI
that had failed to respond to 10 days of high-dose vancomy-
cin, 50 (35.5%) in patients with fulminant CDI, 18 (12.8%) in
patients with a ﬁrst recurrence and ﬁve (3.5%) as primary
therapy. Five (3.5%) would never consider recommending
FMT.
Facilitators and barriers for FMT use
Respondents were asked to report how 11 different factors
inﬂuenced their view of FMT (Table 3). A total of 133/138
(96.4%) believed that the evidence base supported the use of
FMT, but a majority reported that patient acceptance, donor
selection, lack of availability of screened faecal solution, feasi-
bility and local expertise inhibited the uptake of FMT.
When respondents were asked about factors that might
facilitate the uptake of FMT, 135/140 (96.4%) would like access
to a regional protocol and patient information sheet for FMT,
136 (97.1%) would use prescreened faecal solution if it were
available regionally, 131 (93.6%) would like access either on or
off site to a physician experienced in FMT during initial
implementation of an FMT programme and 97 (69.3%) would
like the ability to refer patients to a regional faecal transplant
centre.TABLE 2. Therapy used for CDI
Therapy n (%)
Vancomycin (oral) 160 (99.4)
Metronidazole (oral) 155 (96.3)
Metronidazole (intravenous) 145 (90.1)
Fidaxomicin (oral) 112 (69.6)
Intravenous immunoglobulin 82 (50.9)
Vancomycin (per rectum) 54 (33.5)
Colectomy 43 (26.7)
Faecal microbiota transplant 33 (20.5)
Rifaximin (oral) 27 (16.8)
Cholestyramine 6 (3.7)
Fusidic acid/sodium fusidate (oral) 3 (1.9)
Teicoplanin (oral) 2 (1.2)
Nitazoxanide (oral) 1 (0.6)
Bacitracin (oral) 0 (0.0)
Clostridium difﬁcile infection.
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expenditure. FMT is an option that may reduce mortality,
shorten hospital stays and save the healthcare economy money.
This survey provides the ﬁrst data on UK physician attitudes to
FMT and provides insights into the uptake, beliefs and desires of
those treating these patients at the bedside. There is clearly a
strong risk of selection bias in this form of survey, but it in-
cludes views from 104 of the 746 consultant infection special-
ists in the United Kingdom (Royal College of Physicians, https://
www.rcplondon.ac.uk/sites/default/ﬁles/2011_census_-_
registrar_census_-_intro_and_r1-r20.pdf, and Royal College of
Pathologists, http://www.rcpath.org/Resources/RCPath/
Migrated%20Resources/Documents/C/
careersleaﬂetundergraduates.pdf), and the whole survey rep-
resents a response from nearly one in two (86/183) of all NHS
acute trusts or boards. This survey suggests that uptake of FMT
in the United Kingdom is currently low, with FMT being rec-
ommended less frequently than colectomy, but that there is a
recognition that more patients would beneﬁt from this therapy,
with almost every respondent reporting one or more suitable
patients a year at their place of work.transplantation
Factor
Favours use,
n (%)
Inhibits use,
n (%)
Neither,
n (%)
Don’t know,
n (%)
Evidence base 133 (96.4) 0 (0.0) 2 (1.4) 3 (2.2)
Beneﬁt vs. risk 128 (90.8) 1 (0.7) 8 (5.7) 4 (2.8)
Overall cost 59 (41.8) 14 (9.9) 42 (29.8) 26 (18.4)
Antimicrobial
resistance
86 (61.0) 5 (3.5) 41 (29.1) 9 (6.4)
Patient safety 78 (55.3) 17 (12.1) 37 (26.2) 9 (6.4)
Patient acceptance 33 (23.4) 58 (41.1) 37 (26.2) 13 (9.2)
Donor selection 13 (9.3) 67 (47.9) 45 (32.1) 15 (10.7)
Cost to local
laboratory
14 (10.0) 46 (32.9) 64 (45.7) 16 (11.4)
Availability of
prepared stool
47 (33.6) 66 (47.1) 16 (11.4) 11 (7.9)
Feasibility and
practicality
of procedure
35 (24.8) 81 (57.4) 19 (13.5) 6 (4.3)
Local expertise 45 (32.1) 64 (45.7) 24 (17.1) 7 (5.0)
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favours FMT and that the beneﬁt of this form of therapy out-
weighs the risk. There appears to be understanding about the
high cost of treatment for recurrent CDI—not only a ﬁnancial
cost, but also a cost in terms of antimicrobial resistance in
normal gut ﬂora. However, there remains a belief that patients
may not want FMT, despite evidence to the contrary [13].
Physicians are also rightly concerned about appropriate donor
selection, availability of prescreened stool and the practicality
and feasibility of performing FMT. There is also a recognition
that expertise in the United Kingdom is currently lacking.
When asked if access to regional protocols, patient information
leaﬂets, prescreened stool and expert advice would be
welcomed, there was an overwhelmingly positive response, and
two thirds of respondents would be happy to refer patients to a
regional centre for FMT.
The development of artiﬁcial faecal solution [16] and neater
delivery methods are already in development, but in the interim,
carefully screened donor faeces appears safe in the short term
[11]. The use of frozen faecal solution [17] will improve acces-
sibility to prescreened stool and appears to have a similar efﬁcacy
[18]. Delivering frozen FMT via oral capsule has recently been
reported to have resulted in good outcomes in a small group of
patients. This approach is less invasive, is less time-consuming and
is likely to improve patient acceptability [19].
FMT was recently incorporated into the European Society of
Clinical Microbiology and Infectious Diseases’ treatment
guidelines for recurrent CDI [20]. However, there is an
increasing need for clear national and international guidelines
standardizing the approach to donor screening, as well as the
subsequent preparation, storage and delivery of FMT [21,22].
The governance structures around FMT are yet to be clearly
deﬁned in many countries. In the United States, the US Food
and Drug Administration classed FMT as a drug in May 2013,
requiring an investigational new drug (IND) application to be
submitted before performing FMT. However, shortly after-
wards, the FDA effectively dropped this requirement (http://
www.fda.gov/BiologicsBloodVaccines/
GuidanceComplianceRegulatoryInformation/Guidances/
Vaccines/ucm361379.htm) after concerns that the IND appli-
cation was so onerous that it would greatly restrict uptake of
FMT. The FDA guidance is currently in draft, and further
clariﬁcation is expected to follow. In the United Kingdom, FMT
is regulated under the Human Tissue Act of 2004 and is
overseen by the Human Tissue Authority, which does not
currently provide FMT-speciﬁc guidance. The European Medi-
cines Agency does not recognize FMT as a drug, and as such has
no speciﬁc guidance (personal correspondence).
With regard to funding, the United Kingdom remains behind
the United States, where remuneration for FMT through codingCrown Copyright © 2015 Clinical Microbiology and Infection published by Elsevier Ltd on behalfnow recognizes not only the cost of performing the procedure
but also the cost to the laboratory of donor selection and stool
screening (http://www.gastro.org/practice/coding/aga-provides-
fmt-coding-guidance), whilst the UK National Institute for
Clinical Excellence coding guidance covers the cost of the
procedure only. Centres performing FMT must be able to
recoup their costs or the NHS may end up spending more by
buying from private providers.
The United Kingdom should beneﬁt from having a single,
uniﬁed healthcare provider, and for FMT, this beneﬁt should be
exploited. Service development between the NHS and the
Royal Colleges could lead to national protocols, consent forms
and information. Regional centres could provide FMT or could
act as donor banks for faecal solution, sending out frozen stool
aliquots as required. Awareness amongst primary care and
secondary care physicians could be raised and patient education
supported. As interest in FMT for other common conditions
increases [23], this would potentially put healthcare services on
the front foot.Transparency declarationBoth authors report no conﬂicts of interest relevant to this
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